Surovatamig

Multispecific antibody

Phase 3underway

Evidence outlook · registrational

Follicular Lymphoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2031-11-26.

Also in development:Rheumatoid Arthritis · Phase 1Systemic Lupus Erythematosus · Phase 1Large B-Cell Lymphoma · Phase 3B-Cell Non-Hodgkin Lymphoma · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Follicular Lymphoma
Large B-Cell Lymphoma
Other / comorbidity
NCT07509151 · AstraZeneca
2026-05-05 – 2032-04-05 · Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
What this study did
Phase 2 (2)
B-Cell Non-Hodgkin Lymphoma
NCT06526793 · AstraZeneca
2024-11-27 – 2032-10-21 · B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
What this study did
Other / comorbidity
NCT07571746 · AstraZeneca
2026-03-28 – 2030-04-15 · Primary Membranous Nephropathy
What this study did
Phase 1/2 (3)
B-Cell Non-Hodgkin Lymphoma
NCT06564038 · AstraZeneca
2025-01-30 – 2030-05-20 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
What this study did
NCT07123454 · AstraZeneca
2025-09-24 – 2029-02-15 · B-cell Non-Hodgkin Lymphoma
What this study did
Other / comorbidity
NCT06137118 · AstraZeneca
2023-12-29 – 2028-08-10 · B-cell Acute Lymphoblastic Leukemia (B-ALL)
What this study did
Phase 1 (2)
B-Cell Non-Hodgkin Lymphoma
NCT04594642 · AstraZeneca
2021-03-02 – 2028-06-19 · B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
What this study did
Systemic Lupus Erythematosus

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Surovatamig: this drugPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4512Phase 1/2Antibody–drug conjugateCD22not yet gradedNo reviewed efficacy summary in this indication
JNJ-88998377Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
REGN5837Phase 1Multispecific antibodyCD22 x CD28not yet gradedNo reviewed efficacy summary in this indication
SHR-3079Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
XmAb657
Phase 1(overall)
Multispecific antibodyCD19 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication
Vispacabtagene RegedleucelDiscontinuedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Surovatamig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (6)
January 2028 (1)
Phase 1/2B-cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting
Est. primary completion 2028-01-06 · NCT06137118 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-04-21 · NCT06526793 · CT.gov ↗
What to watch
June 2028 (2)
Phase 1Follicular LymphomaActive not recruiting
Est. primary completion 2028-06-19 · NCT04594642 · CT.gov ↗
What to watch
Phase 1Rheumatoid ArthritisRecruiting
Est. primary completion 2028-06-27 · NCT07201558 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1/2B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2028-07-04 · NCT07123454 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Primary Membranous NephropathyRecruiting
Est. primary completion 2028-10-13 · NCT07571746 · CT.gov ↗
What to watch
2030 (3)
May 2030 (1)
Phase 1/2Large B-Cell LymphomaRecruiting
Est. primary completion 2030-05-20 · NCT06564038 · CT.gov ↗
What to watch
June 2030 (1)
Phase 3Large B-Cell LymphomaRecruiting
Est. primary completion 2030-06-10 · NCT07215585 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2030-09-02 · NCT07911553 · CT.gov ↗
What to watch
2031 (2)
August 2031 (1)
Phase 3Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVRecruiting
Est. primary completion 2031-08-29 · NCT07509151 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2031-11-26 · NCT06549595 · CT.gov ↗
What to watch
2035 (1)
January 2035 (1)
Phase 3Follicular LymphomaNot yet recruiting
Est. primary completion 2035-01-13 · NCT07736950 · CT.gov ↗
What to watch

See the full readout calendar ↗